Adaptive updated their IPO filing on 6/26/19 and raised their potential raise to $327 million from $230 million listed in their original filing. The company currently offers tools for monitoring several cancer types, sequencing immune system components, and aiding drug discovery.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,